{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:36:13Z","timestamp":1794537373545,"version":"4.9.1"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41574-019-0305-4","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T08:02:37Z","timestamp":1577692957000},"page":"104-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":278,"title":["New insights into the pathogenesis and nonsurgical management of Graves orbitopathy"],"prefix":"10.1038","volume":"16","author":[{"given":"Peter N.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W. J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2926-0722","authenticated-orcid":false,"given":"Ilaria","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Ezra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin M.","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Kahaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Ludgate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"305_CR1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith, T. J. & Hegedus, L. Graves\u2019 disease. N. Engl. J.\u00a0Med. 375, 1552\u20131565 (2016).","journal-title":"N. Engl. J. Med."},{"key":"305_CR2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn, R. S. Graves\u2019 ophthalmopathy. N. Engl. J. Med. 362, 726\u2013738 (2010).","journal-title":"N. Engl. J. Med."},{"key":"305_CR3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ajo.2011.02.018","volume":"152","author":"KA Ponto","year":"2011","unstructured":"Ponto, K. A. et al. Quality of life in a German Graves orbitopathy population. Am. J. Ophthalmol. 152, 483\u2013490 (2011).","journal-title":"Am. J. Ophthalmol."},{"key":"305_CR4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","volume":"63","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly, G. J., Petrak, F., Hardt, J., Pitz, S. & Egle, U. T. Psychosocial morbidity of Graves\u2019 orbitopathy. Clin.\u00a0Endocrinol. (Oxf.) 63, 395\u2013402 (2005).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"305_CR5","doi-asserted-by":"crossref","unstructured":"Wiersinga, W. M. & Kahaly, G. J. Graves\u2019 orbitopathy:\u00a0a multidisciplinary approach. 3rd edn, (Karger, 2017).","DOI":"10.1159\/isbn.978-3-318-06085-0"},{"key":"305_CR6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1210\/jc.2012-3119","volume":"98","author":"KA Ponto","year":"2013","unstructured":"Ponto, K. A. et al. Public health relevance of Graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 98, 145\u2013152 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","volume":"388","author":"S De Leo","year":"2016","unstructured":"De Leo, S., Lee, S. Y. & Braverman, L. E. Hyperthyroidism. Lancet 388, 906\u2013918 (2016).","journal-title":"Lancet"},{"key":"305_CR8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","volume":"14","author":"PN Taylor","year":"2018","unstructured":"Taylor, P. N. et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol. 14, 301\u2013316 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"305_CR9","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0625-1","volume":"12","author":"P Perros","year":"2017","unstructured":"Perros, P. et al. Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement. Orphanet J. Rare Dis. 12, 72 (2017).","journal-title":"Orphanet J. Rare Dis."},{"key":"305_CR10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-18-0039","volume":"178","author":"W Wiersinga","year":"2018","unstructured":"Wiersinga, W. et al. Predictive score for the development or progression of Graves\u2019 orbitopathy in patients with newly diagnosed Graves\u2019 hyperthyroidism. Eur. J. Endocrinol. 178, 635\u2013643 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"305_CR11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/thy.2010.1618","volume":"20","author":"P Perros","year":"2010","unstructured":"Perros, P. & Wiersinga, W. M. The Amsterdam declaration on Graves\u2019 orbitopathy. Thyroid 20, 245\u2013246 (2010).","journal-title":"Thyroid"},{"key":"305_CR12","first-page":"1409","volume":"84","author":"C Hansen","year":"1999","unstructured":"Hansen, C., Rouhi, R., Forster, G. & Kahaly, G. J. Increased sulfatation of orbital glycosaminoglycans in Graves\u2019 ophthalmopathy. J. Clin. Endocrinol. Metab. 84, 1409\u20131413 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/187152211795495689","volume":"11","author":"S Zang","year":"2011","unstructured":"Zang, S. & Kahaly, G. Steroids and the immune response in Graves orbitopathy. Immunol. Endocr. Metab. Agents Med. Chem. 11, 90\u201398 (2011).","journal-title":"Immunol. Endocr. Metab. Agents Med. Chem."},{"key":"305_CR14","first-page":"101373","volume":"5","author":"RA Lee","year":"2018","unstructured":"Lee, R. A., Harris, C. A. & Wang, J. C. Glucocorticoid receptor and adipocyte biology. Nucl. Receptor Res. 5, 101373 (2018).","journal-title":"Nucl. Receptor Res."},{"key":"305_CR15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1210\/jc.2009-0873","volume":"95","author":"JW Tomlinson","year":"2010","unstructured":"Tomlinson, J. W. et al. The role of 11beta-hydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab. 95, 398\u2013406 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1677\/JOE-06-0042","volume":"192","author":"IJ Bujalska","year":"2007","unstructured":"Bujalska, I. J. et al. Characterisation of 11beta-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat. J. Endocrinol. 192, 279\u2013288 (2007).","journal-title":"J. Endocrinol."},{"key":"305_CR17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena, L. et al. Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on\u00a0management of GO. Eur. J. Endocrinol. 158, 273\u2013285 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"305_CR18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.iop.0000235499.34867.85","volume":"22","author":"PJ Dolman","year":"2006","unstructured":"Dolman, P. J. & Rootman, J. VISA classification for Graves orbitopathy. Ophthalmic Plast. Reconstr. Surg. 22, 319\u2013324 (2006).","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"305_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits, M. P., Prummel, M. F., Wiersinga, W. M. & Koornneef, L. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin. Endocrinol. (Oxf.) 47, 9\u201314 (1997).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"305_CR20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9394(69)91246-X","volume":"68","author":"SC Werner","year":"1969","unstructured":"Werner, S. C. Classification of the eye changes of Graves\u2019 disease. Am. J. Ophthalmol. 68, 646\u2013648 (1969).","journal-title":"Am. J. Ophthalmol."},{"key":"305_CR21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1210\/jcem-44-1-203","volume":"44","author":"SC Werner","year":"1977","unstructured":"Werner, S. C. Modification of the classification of the eye changes of Graves\u2019 disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J. Clin. Endocrinol. Metab. 44, 203\u2013204 (1977).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","volume":"38","author":"P Perros","year":"1993","unstructured":"Perros, P., Crombie, A. L., Matthews, J. N. & Kendall-Taylor, P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin. Endocrinol. (Oxf.) 38, 367\u2013372 (1993).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"305_CR23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena, L. et al. The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur. Thyroid. J. 5, 9\u201326 (2016).","journal-title":"Eur. Thyroid. J."},{"key":"305_CR24","doi-asserted-by":"crossref","first-page":"249125","DOI":"10.1155\/2015\/249125","volume":"2015","author":"J Barrio-Barrio","year":"2015","unstructured":"Barrio-Barrio, J., Sabater, A. L., Bonet-Farriol, E., Velazquez-Villoria, A. & Galofre, J. C. Graves\u2019 ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J. Ophthalmol. 2015, 249125 (2015).","journal-title":"J. Ophthalmol."},{"key":"305_CR25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","volume":"18","author":"L Bartalena","year":"2008","unstructured":"Bartalena, L. et al. Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on\u00a0management of Graves\u2019 orbitopathy. Thyroid 18, 333\u2013346 (2008).","journal-title":"Thyroid"},{"key":"305_CR26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","volume":"54","author":"CB Terwee","year":"2001","unstructured":"Terwee, C. B. et al. Interpretation and validity of changes in scores on the Graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin. Endocrinol. (Oxf.) 54, 391\u2013398 (2001).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"305_CR27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.82.7.773","volume":"82","author":"CB Terwee","year":"1998","unstructured":"Terwee, C. B., Gerding, M. N., Dekker, F. W., Prummel,\u00a0M. F. & Wiersinga, W. M. Development of a\u00a0disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL. Br. J. Ophthalmol. 82, 773\u2013779 (1998).","journal-title":"Br. J. Ophthalmol."},{"key":"305_CR28","first-page":"1341","volume":"23","author":"A Dietrich","year":"2018","unstructured":"Dietrich, A. et al. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial. Psychol. Health Med 23, 1341\u20131355 (2018).","journal-title":"Psychol. Health Med"},{"key":"305_CR29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","volume":"6","author":"R Rajendram","year":"2018","unstructured":"Rajendram, R. et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 \u00d7 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol 6, 299\u2013309 (2018).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"305_CR30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly, G. J. et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet. Diabetes Endocrinol. 6, 287\u2013298 (2018).","journal-title":"Lancet. Diabetes Endocrinol."},{"key":"305_CR31","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/bjophthalmol-2015-306733","volume":"99","author":"P Perros","year":"2015","unstructured":"Perros, P. et al. PREGO (presentation of Graves\u2019 orbitopathy) study: changes in referral patterns to European Group On Graves\u2019 Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br. J. Ophthalmol. 99, 1531\u20131535 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"305_CR32","unstructured":"British Thyroid Foundation. TEAMeD-5, http:\/\/www.btf-thyroid.org\/TEAMeD-5 (2018)."},{"key":"305_CR33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/acta.0.1200473","volume":"120","author":"C Marcocci","year":"1989","unstructured":"Marcocci, C., Bartalena, L., Bogazzi, F., Panicucci, M. & Pinchera, A. Studies on the occurrence of ophthalmopathy in Graves\u2019 disease. Acta Endocrinol. 120, 473\u2013478 (1989).","journal-title":"Acta Endocrinol."},{"key":"305_CR34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1210\/jc.2010-2329","volume":"96","author":"L Bartalena","year":"2011","unstructured":"Bartalena, L. The dilemma of how to manage Graves\u2019 hyperthyroidism in patients with associated orbitopathy. J. Clin. Endocrinol. Metab. 96, 592\u2013599 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/BF03350047","volume":"12","author":"L Bartalena","year":"1989","unstructured":"Bartalena, L. et al. More on smoking habits and Graves\u2019 ophthalmopathy. J. Endocrinol. Invest. 12, 733\u2013737 (1989).","journal-title":"J. Endocrinol. Invest."},{"key":"305_CR36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cen.12222","volume":"79","author":"WM Wiersinga","year":"2013","unstructured":"Wiersinga, W. M. Smoking and thyroid. Clin. Endocrinol. (Oxf.) 79, 145\u2013151 (2013).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"305_CR37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","volume":"269","author":"MF Prummel","year":"1993","unstructured":"Prummel, M. F. & Wiersinga, W. M. Smoking and risk of Graves\u2019 disease. Jama 269, 479\u2013482 (1993).","journal-title":"Jama"},{"key":"305_CR38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","volume":"129","author":"L Bartalena","year":"1998","unstructured":"Bartalena, L. et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann. Intern. Med. 129, 632\u2013635 (1998).","journal-title":"Ann. Intern. Med."},{"key":"305_CR39","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.87.6.773","volume":"87","author":"A Eckstein","year":"2003","unstructured":"Eckstein, A. et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br. J. Ophthalmol. 87, 773\u2013776 (2003).","journal-title":"Br. J. Ophthalmol."},{"key":"305_CR40","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","volume":"45","author":"J Pfeilschifter","year":"1996","unstructured":"Pfeilschifter, J. & Ziegler, R. Smoking and endocrine ophthalmopathy: impact of smoking severity and\u00a0current vs lifetime cigarette consumption. Clin.\u00a0Endocrinol. (Oxf.) 45, 477\u2013481 (1996).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"305_CR41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/jc.2006-1824","volume":"92","author":"TJ Cawood","year":"2007","unstructured":"Cawood, T. J., Moriarty, P., O\u2019Farrelly, C. & O\u2019Shea, D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J. Clin. Endocrinol. Metab. 92, 59\u201364 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2010.0218","volume":"21","author":"NI Regensburg","year":"2011","unstructured":"Regensburg, N. I., Wiersinga, W. M., Berendschot, T. T., Saeed, P. & Mourits, M. P. Effect of smoking on orbital fat and muscle volume in Graves\u2019 orbitopathy. Thyroid 21, 177\u2013181 (2011).","journal-title":"Thyroid"},{"key":"305_CR43","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci, C. et al. Selenium and the course of mild Graves\u2019 orbitopathy. N. Engl. J. Med. 364, 1920\u20131931 (2011).","journal-title":"N. Engl. J. Med."},{"key":"305_CR44","first-page":"3562","volume":"86","author":"C Marcocci","year":"2001","unstructured":"Marcocci, C. et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study. J. Clin. Endocrinol. Metab. 86, 3562\u20133567 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR45","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly, G. J., Pitz, S., Hommel, G. & Dittmar, M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J.\u00a0Clin. Endocrinol. Metab. 90, 5234\u20135240 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR46","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena, L., Pinchera, A. & Marcocci, C. Management of Graves\u2019 ophthalmopathy: reality and perspectives. Endocr. Rev. 21, 168\u2013199 (2000).","journal-title":"Endocr. Rev."},{"key":"305_CR47","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena, L. et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 97, 4454\u20134463 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cen.13170","volume":"86","author":"X Ye","year":"2017","unstructured":"Ye, X. et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy. Clin. Endocrinol. (Oxf.) 86, 247\u2013255 (2017).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"305_CR49","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","volume":"321","author":"MF Prummel","year":"1989","unstructured":"Prummel, M. F. et al. Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy. N.\u00a0Engl. J. Med. 321, 1353\u20131359 (1989).","journal-title":"N. Engl. J. Med."},{"key":"305_CR50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","volume":"7","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly, G. J. et al. 2018 European Thyroid Association guideline for the management of Graves\u2019 hyperthyroidism. Eur. Thyroid. J. 7, 167\u2013186 (2018).","journal-title":"Eur. Thyroid. J."},{"key":"305_CR51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(16)30046-8","volume":"5","author":"WM Wiersinga","year":"2017","unstructured":"Wiersinga, W. M. Advances in treatment of active, moderate-to-severe Graves\u2019 ophthalmopathy. lancet. Diabetes & Endocrinol. 5, 134\u2013142 (2017).","journal-title":"lancet. Diabetes & Endocrinol."},{"key":"305_CR52","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1055\/s-0035-1554721","volume":"47","author":"M Salvi","year":"2015","unstructured":"Salvi, M. & Campi, I. Medical treatment of Graves\u2019 orbitopathy. Horm. Metab. Res. 47, 779\u2013788 (2015).","journal-title":"Horm. Metab. Res."},{"key":"305_CR53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang, S., Ponto, K. A. & Kahaly, G. J. Clinical review: intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J. Clin. Endocrinol. Metab. 96, 320\u2013332 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR54","doi-asserted-by":"crossref","first-page":"E1523","DOI":"10.1210\/jc.2015-2976","volume":"100","author":"N Matheis","year":"2015","unstructured":"Matheis, N. et al. Proteomics of orbital tissue in thyroid-associated orbitopathy. J. Clin. Endocrinol. Metab. 100, E1523\u2013E1530 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR55","first-page":"102","volume":"85","author":"GJ Kahaly","year":"2000","unstructured":"Kahaly, G. J., Rosler, H. P., Pitz, S. & Hommel, G. Low- versus high-dose radiotherapy for Graves\u2019 ophthalmopathy: a randomized, single blind trial. J.\u00a0Clin. Endocrinol. Metab. 85, 102\u2013108 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1210\/jc.2003-030809","volume":"89","author":"MF Prummel","year":"2004","unstructured":"Prummel, M. F. et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves\u2019 ophthalmopathy. J. Clin. Endocrinol. Metab. 89, 15\u201320 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR57","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0140-6736(93)92001-A","volume":"342","author":"MF Prummel","year":"1993","unstructured":"Prummel, M. F. et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves\u2019 ophthalmopathy. Lancet 342, 949\u2013954 (1993).","journal-title":"Lancet"},{"key":"305_CR58","first-page":"2327","volume":"86","author":"E Christiansen","year":"2001","unstructured":"Christiansen, E. & Kofoed-Enevoldsen, A. Graves\u2019 ophthalmopathy. J. Clin. Endocrinol. Metab. 86, 2327\u20132328 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR59","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0161-6420(01)00632-7","volume":"108","author":"CA Gorman","year":"2001","unstructured":"Gorman, C. A. et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves\u2019 ophthalmopathy. Ophthalmology 108, 1523\u20131534 (2001).","journal-title":"Ophthalmology"},{"key":"305_CR60","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","volume":"355","author":"MP Mourits","year":"2000","unstructured":"Mourits, M. P. et al. Radiotherapy for Graves\u2019 orbitopathy: randomised placebo-controlled study. Lancet 355, 1505\u20131509 (2000).","journal-title":"Lancet"},{"key":"305_CR61","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1097\/IOP.0000000000001186","volume":"34","author":"KJ Godfrey","year":"2018","unstructured":"Godfrey, K. J. & Kazim, M. Radiotherapy for active thyroid eye disease. Ophthalmic Plast. Reconstr. Surg. 34, S98\u2013S104 (2018).","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"305_CR62","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/eye.2012.284","volume":"27","author":"DH Verity","year":"2013","unstructured":"Verity, D. H. & Rose, G. E. Acute thyroid eye disease (TED): principles of medical and surgical management. Eye (Lond.) 27, 308\u2013319 (2013).","journal-title":"Eye (Lond.)"},{"key":"305_CR63","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1749-6632.1993.tb35881.x","volume":"685","author":"EM Eugui","year":"1993","unstructured":"Eugui, E. M. & Allison, A. C. Immunosuppressive activity of mycophenolate mofetil. Ann. NY Acad. Sci. 685, 309\u2013329 (1993).","journal-title":"Ann. NY Acad. Sci."},{"key":"305_CR64","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/S0041-1345(02)03538-8","volume":"34","author":"AC Allison","year":"2002","unstructured":"Allison, A. C. Mechanisms of action of mycophenolate mofetil in preventing chronic rejection. Transplant. Proc. 34, 2863\u20132866 (2002).","journal-title":"Transplant. Proc."},{"key":"305_CR65","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40618-016-0441-9","volume":"39","author":"M Riedl","year":"2016","unstructured":"Riedl, M., Kuhn, A., Kramer, I., Kolbe, E. & Kahaly, G. J. Prospective, systematically recorded mycophenolate safety data in Graves\u2019 orbitopathy. J. Endocrinol. Invest. 39, 687\u2013694 (2016).","journal-title":"J. Endocrinol. Invest."},{"key":"305_CR66","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1749-6632.1993.tb35881.x","volume":"685","author":"EM Eugui","year":"1993","unstructured":"Eugui, E. M. & Allison, A. C. Immunosuppressive activity of mycophenolate mofetil. Ann. NY Acad. Sci. 685, 309\u2013329 (1993).","journal-title":"Ann. NY Acad. Sci."},{"key":"305_CR67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbi.2018.09.020","volume":"75","author":"AG Mazumder","year":"2019","unstructured":"Mazumder, A. G., Patial, V. & Singh, D. Mycophenolate mofetil contributes to downregulation of the hippocampal interleukin type 2 and 1beta mediated PI3K\/AKT\/mTOR pathway hyperactivation and attenuates neurobehavioral comorbidities in a rat model of temporal lobe epilepsy. Brain, Behav. Immun. 75, 84\u201393 (2019).","journal-title":"Brain, Behav. Immun."},{"key":"305_CR68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1530\/acta.0.1220008","volume":"122","author":"P Perros","year":"1990","unstructured":"Perros, P., Weightman, D. R., Crombie, A. L. & Kendall-Taylor, P. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol. 122, 8\u201312 (1990).","journal-title":"Acta Endocrinol."},{"key":"305_CR69","first-page":"167","volume":"7","author":"TJ Smith","year":"2016","unstructured":"Smith, T. J. & Janssen, J. A. Building the case for insulin-like growth factor receptor-1 involvement in thyroid-associated ophthalmopathy. Front. Endocrinol. 7, 167 (2016).","journal-title":"Front. Endocrinol."},{"key":"305_CR70","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","volume":"40","author":"TJ Smith","year":"2016","unstructured":"Smith, T. J. & Janssen, J. Insulin-like growth factor-1 receptor and thyroid-associated ophthalmopathy. Endocr. Rev. 40, 236\u2013267 (2016).","journal-title":"Endocr. Rev."},{"key":"305_CR71","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","volume":"170","author":"J Pritchard","year":"2003","unstructured":"Pritchard, J., Han, R., Horst, N., Cruikshank, W. W. &\u00a0Smith, T. J. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the\u00a0insulin-like growth factor 1 receptor pathway. J.\u00a0Immunol. 170, 6348\u20136354 (2003).","journal-title":"J. Immunol."},{"key":"305_CR72","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.beem.2011.10.002","volume":"26","author":"TJ Smith","year":"2012","unstructured":"Smith, T. J., Hegedus, L. & Douglas, R. S. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves\u2019 orbitopathy. Best. Pract. Clin. Endocrinol. Metab. 26, 291\u2013302 (2012).","journal-title":"Best. Pract. Clin. Endocrinol. Metab."},{"key":"305_CR73","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith, T. J. et al. Teprotumumab for thyroid-associated ophthalmopathy. N. Engl. J. Med. 376, 1748\u20131761 (2017).","journal-title":"N. Engl. J. Med."},{"key":"305_CR74","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LD Piro","year":"1999","unstructured":"Piro, L. D. et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann. Oncol. 10, 655\u2013661 (1999).","journal-title":"Ann. Oncol."},{"key":"305_CR75","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan, M. N. et al. Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 100, 432\u2013441 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR76","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi, M. et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J.\u00a0Clin. Endocrinol. Metab. 100, 422\u2013431 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR77","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-16-0552","volume":"176","author":"MN Stan","year":"2017","unstructured":"Stan, M. N. & Salvi, M. Management of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy \u2014 lessons from randomized control trials. Eur. J. Endocrinol. 176, R101\u2013R109 (2017).","journal-title":"Eur. J. Endocrinol."},{"key":"305_CR78","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41433-018-0285-y","volume":"33","author":"M Salvi","year":"2019","unstructured":"Salvi, M. & Covelli, D. B cells in Graves\u2019 orbitopathy: more than just a source of antibodies? Eye (Lond.) 33, 230\u2013234 (2019).","journal-title":"Eye (Lond.)"},{"key":"305_CR79","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","volume":"30","author":"JV Perez-Moreiras","year":"2014","unstructured":"Perez-Moreiras, J. V., Alvarez-Lopez, A. & Gomez, E. C. Treatment of active corticosteroid-resistant graves\u2019 orbitopathy. Ophthalmic Plast. Reconstr. Surg. 30, 162\u2013167 (2014).","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"305_CR80","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ajoc.2017.07.001","volume":"7","author":"DJ Russell","year":"2017","unstructured":"Russell, D. J., Wagner, L. H. & Seiff, S. R. Tocilizumab as a steroid sparing agent for the treatment of Graves\u2019 orbitopathy. Am. J. Ophthalmol. Case Rep. 7, 146\u2013148 (2017).","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"305_CR81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras, J. V. et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. Am. J. Ophthalmol. 195, 181\u2013190 (2018).","journal-title":"Am. J. Ophthalmol."},{"key":"305_CR82","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/1744666X.2017.1291343","volume":"13","author":"W Stohl","year":"2017","unstructured":"Stohl, W. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE). Expert. Rev. Clin. Immunol. 13, 623\u2013633 (2017).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"305_CR83","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1089\/thy.2013.0194","volume":"23","author":"MS Draman","year":"2013","unstructured":"Draman, M. S. et al. Effects of prostaglandin F2alpha on adipocyte biology relevant to graves\u2019 orbitopathy. Thyroid 23, 1600\u20131608 (2013).","journal-title":"Thyroid"},{"key":"305_CR84","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/thy.2018.0506","volume":"29","author":"MS Draman","year":"2019","unstructured":"Draman, M. S. et al. Prostaglandin F2-alpha eye drops (bimatoprost) in Graves\u2019 orbitopathy: a randomized controlled double-masked crossover trial (BIMA trial). Thyroid 29, 563\u2013572 (2019).","journal-title":"Thyroid"},{"key":"305_CR85","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1167\/iovs.15-16580","volume":"56","author":"K Kozdon","year":"2015","unstructured":"Kozdon, K., Fitchett, C., Rose, G. E., Ezra, D. G. &\u00a0Bailly, M. Mesenchymal stem cell-like properties of orbital fibroblasts in Graves\u2019 orbitopathy. Invest. Ophthalmol. Vis. Sci. 56, 5743\u20135750 (2015).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"305_CR86","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1167\/iovs.15-16610","volume":"56","author":"S Brandau","year":"2015","unstructured":"Brandau, S. et al. Orbital fibroblasts from Graves\u2019 orbitopathy patients share functional and immunophenotypic properties with mesenchymal stem\/stromal cells. Investig. Ophthalmol. Vis. Sci. 56, 6549\u20136557 (2015).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"305_CR87","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1677\/jme.0.0300369","volume":"30","author":"KJ Starkey","year":"2003","unstructured":"Starkey, K. J. et al. Adipose thyrotrophin receptor expression is elevated in Graves\u2019 and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J. Mol. Endocrinol. 30, 369\u2013380 (2003).","journal-title":"J. Mol. Endocrinol."},{"key":"305_CR88","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1530\/EJE-14-1140","volume":"173","author":"PW Potgieser","year":"2015","unstructured":"Potgieser, P. W., Wiersinga, W. M., Regensburg, N. I. &\u00a0Mourits, M. P. Some studies on the natural history of Graves\u2019 orbitopathy: increase in orbital fat is a rather late phenomenon. Eur. J. Endocrinol. 173, 149\u2013153 (2015).","journal-title":"Eur. J. Endocrinol."},{"key":"305_CR89","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2249.2005.02824.x","volume":"141","author":"TJ Smith","year":"2005","unstructured":"Smith, T. J. Insights into the role of fibroblasts in human autoimmune diseases. Clin. Exp. Immunol. 141, 388\u2013397 (2005).","journal-title":"Clin. Exp. Immunol."},{"key":"305_CR90","doi-asserted-by":"crossref","first-page":"895901","DOI":"10.1155\/2008\/895901","volume":"2008","author":"GM Lehmann","year":"2008","unstructured":"Lehmann, G. M., Garcia-Bates, T. M., Smith, T. J., Feldon, S. E. & Phipps, R. P. Regulation of lymphocyte function by PPARgamma: relevance to thyroid eye disease-related inflammation. PPAR Res. 2008, 895901 (2008).","journal-title":"PPAR Res."},{"key":"305_CR91","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2010-1424","volume":"96","author":"GJ Kahaly","year":"2011","unstructured":"Kahaly, G. J. et al. Regulatory T-cells in Graves\u2019 orbitopathy: baseline findings and immunomodulation by anti-T lymphocyte globulin. J. Clin. Endocrinol. Metab. 96, 422\u2013429 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR92","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/jc.2009-1614","volume":"95","author":"RS Douglas","year":"2010","unstructured":"Douglas, R. S. et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab. 95, 430\u2013438 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR93","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1167\/iovs.18-23951","volume":"59","author":"Y Lu","year":"2018","unstructured":"Lu, Y. et al. CD34\u2013 orbital fibroblasts from patients with thyroid-associated ophthalmopathy modulate TNF-alpha expression in CD34+ fibroblasts and fibrocytes. Investig. Ophthalmol. Vis. Sci. 59, 2615\u20132622 (2018).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"305_CR94","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1073\/pnas.1202064109","volume":"109","author":"R Fernando","year":"2012","unstructured":"Fernando, R. et al. Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proc. Natl Acad. Sci. USA 109, 7427\u20137432 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"305_CR95","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaophthalmol.2018.0806","volume":"136","author":"G Rotondo Dottore","year":"2018","unstructured":"Rotondo Dottore, G. et al. Association of T and B cells infiltrating orbital tissues with clinical features of graves orbitopathy. JAMA Ophthalmol. 136, 613\u2013619 (2018).","journal-title":"JAMA Ophthalmol."},{"key":"305_CR96","doi-asserted-by":"crossref","first-page":"412158","DOI":"10.1155\/2014\/412158","volume":"2014","author":"P Pawlowski","year":"2014","unstructured":"Pawlowski, P. et al. Markers of inflammation and fibrosis in the orbital fat\/connective tissue of patients with Graves\u2019 orbitopathy: clinical implications. Mediators. Inflamm. 2014, 412158 (2014).","journal-title":"Mediators. Inflamm."},{"key":"305_CR97","doi-asserted-by":"crossref","first-page":"E400","DOI":"10.1210\/jc.2011-2697","volume":"97","author":"L van Steensel","year":"2012","unstructured":"van Steensel, L. et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves\u2019 ophthalmopathy. J. Clin. Endocrinol. Metab. 97, E400\u2013E408 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR98","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17469899.2016.1202113","volume":"11","author":"MS Draman","year":"2016","unstructured":"Draman, M. S. & Ludgate, M. Thyroid eye disease \u2014 an update. Expert. Rev. Ophthalmol. 11, 273\u2013284 (2016).","journal-title":"Expert. Rev. Ophthalmol."},{"key":"305_CR99","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui, S. et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J. Immunol. 181, 4397\u20134405 (2008).","journal-title":"J. Immunol."},{"key":"305_CR100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08916939309014643","volume":"16","author":"DR Weightman","year":"1993","unstructured":"Weightman, D. R., Perros, P., Sherif, I. H. & Kendall-Taylor, P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 16, 251\u2013257 (1993).","journal-title":"Autoimmunity"},{"key":"305_CR101","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1210\/en.2013-1576","volume":"154","author":"S Moshkelgosha","year":"2013","unstructured":"Moshkelgosha, S., So, P. W., Deasy, N., Diaz-Cano, S. & Banga, J. P. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves\u2019 orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology 154, 3008\u20133015 (2013).","journal-title":"Endocrinology"},{"key":"305_CR102","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1210\/en.2015-1829","volume":"157","author":"U Berchner-Pfannschmidt","year":"2016","unstructured":"Berchner-Pfannschmidt, U. et al. Comparative assessment of female mouse model of Graves\u2019 orbitopathy under different environments, accompanied by proinflammatory cytokine and T-cell responses to thyrotropin hormone receptor antigen. Endocrinology 157, 1673\u20131682 (2016).","journal-title":"Endocrinology"},{"key":"305_CR103","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0140-6736(93)91475-2","volume":"342","author":"A Feliciello","year":"1993","unstructured":"Feliciello, A. et al. Expression of thyrotropin-receptor mRNA in healthy and Graves\u2019 disease retro-orbital tissue. Lancet 342, 337\u2013338 (1993).","journal-title":"Lancet"},{"key":"305_CR104","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1210\/jcem.82.6.2003","volume":"82","author":"MS Crisp","year":"1997","unstructured":"Crisp, M. S., Lane, C., Halliwell, M., Wynford-Thomas, D. & Ludgate, M. Thyrotropin receptor transcripts in human adipose tissue. J. Clin. Endocrinol. Metab. 82, 2003\u20132005 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR105","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/bjo.2004.050807","volume":"89","author":"A Boschi","year":"2005","unstructured":"Boschi, A. et al. Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy. Br. J. Ophthalmol. 89, 724\u2013729 (2005).","journal-title":"Br. J. Ophthalmol."},{"key":"305_CR106","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/thy.1998.8.411","volume":"8","author":"M Ludgate","year":"1998","unstructured":"Ludgate, M. et al. The thyrotropin receptor in thyroid eye disease. Thyroid 8, 411\u2013413 (1998).","journal-title":"Thyroid"},{"key":"305_CR107","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1167\/iovs.06-0596","volume":"47","author":"L Zhang","year":"2006","unstructured":"Zhang, L. et al. Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Investig. Ophthalmol. Vis. Sci. 47, 5197\u20135203 (2006).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"305_CR108","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1677\/JOE-07-0452","volume":"196","author":"M Lu","year":"2008","unstructured":"Lu, M. & Lin, R. Y. TSH stimulates adipogenesis in mouse embryonic stem cells. J. Endocrinol. 196, 159\u2013169 (2008).","journal-title":"J. Endocrinol."},{"key":"305_CR109","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/JME-11-0006","volume":"46","author":"S Kumar","year":"2011","unstructured":"Kumar, S., Nadeem, S., Stan, M. N., Coenen, M. &\u00a0Bahn, R. S. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves\u2019 ophthalmopathy. J. Mol. Endocrinol. 46, 155\u2013163 (2011).","journal-title":"J. Mol. Endocrinol."},{"key":"305_CR110","doi-asserted-by":"crossref","first-page":"26447","DOI":"10.1074\/jbc.M109.003616","volume":"284","author":"L Zhang","year":"2009","unstructured":"Zhang, L. et al. Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction. J. Biol. Chem. 284, 26447\u201326455 (2009).","journal-title":"J. Biol. Chem."},{"key":"305_CR111","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1210\/en.2010-0424","volume":"151","author":"SA Morshed","year":"2010","unstructured":"Morshed, S. A., Ando, T., Latif, R. & Davies, T. F. Neutral antibodies to the TSH receptor are present in Graves\u2019 disease and regulate selective signaling cascades. Endocrinology 151, 5537\u20135549 (2010).","journal-title":"Endocrinology"},{"key":"305_CR112","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1210\/jc.2011-1299","volume":"97","author":"L Zhang","year":"2012","unstructured":"Zhang, L. et al. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 97, 653\u2013662 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR113","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12015-011-9242-x","volume":"8","author":"N Billon","year":"2012","unstructured":"Billon, N. & Dani, C. Developmental origins of the adipocyte lineage: new insights from genetics and genomics studies. Stem Cell Rev. 8, 55\u201366 (2012).","journal-title":"Stem Cell Rev."},{"key":"305_CR114","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cell.2007.10.004","volume":"131","author":"S Gesta","year":"2007","unstructured":"Gesta, S., Tseng, Y. H. & Kahn, C. R. Developmental origin of fat: tracking obesity to its source. Cell 131, 242\u2013256 (2007).","journal-title":"Cell"},{"key":"305_CR115","unstructured":"DeGroot, L. J. in Endotext (eds K. R. Feingold et al.) 1\u2013135 (MDText.com, Inc., 2000)."},{"key":"305_CR116","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2214\/ajr.146.3.459","volume":"146","author":"RG Peyster","year":"1986","unstructured":"Peyster, R. G., Ginsberg, F., Silber, J. H. & Adler, L. P. Exophthalmos caused by excessive fat: CT volumetric analysis and differential diagnosis. AJR. Am. J.\u00a0Roentgenol. 146, 459\u2013464 (1986).","journal-title":"AJR. Am. J. Roentgenol."},{"key":"305_CR117","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000076885","volume":"36","author":"MH Smolders","year":"2004","unstructured":"Smolders, M. H. et al. Exophthalmos in obesity. Ophthalmic. Res. 36, 78\u201381 (2004).","journal-title":"Ophthalmic. Res."},{"key":"305_CR118","doi-asserted-by":"crossref","first-page":"E1183","DOI":"10.1210\/jc.2013-4182","volume":"99","author":"L Zhang","year":"2014","unstructured":"Zhang, L. et al. Possible targets for nonimmunosuppressive therapy of Graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 99, E1183\u2013E1190 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR119","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1210\/jc.2016-1315","volume":"101","author":"CC Krieger","year":"2016","unstructured":"Krieger, C. C. et al. TSH\/IGF-1 receptor cross talk in Graves\u2019 ophthalmopathy pathogenesis. J. Clin. Endocrinol. Metab. 101, 2340\u20132347 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR120","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1210\/jc.2014-3566","volume":"100","author":"CC Krieger","year":"2015","unstructured":"Krieger, C. C., Neumann, S., Place, R. F., Marcus-Samuels, B. & Gershengorn, M. C. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves\u2019 disease immunoglobins. J. Clin. Endocrinol. Metab. 100, 1071\u20131077 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR121","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1210\/jc.2015-2932","volume":"101","author":"L Zhang","year":"2016","unstructured":"Zhang, L. et al. Reversal of pathological features of Graves\u2019 orbitopathy by activation of forkhead transcription factors, FOXOs. J. Clin. Endocrinol. Metab. 101, 114\u2013122 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR122","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/thy.2015.0254","volume":"25","author":"S Kumar","year":"2015","unstructured":"Kumar, S., Coenen, M., Iyer, S. & Bahn, R. S. Forkhead transcription factor FOXO1 is regulated by both a stimulatory thyrotropin receptor antibody and insulin-like growth factor-1 in orbital fibroblasts from patients with Graves\u2019 ophthalmopathy. Thyroid 25, 1145\u20131150 (2015).","journal-title":"Thyroid"},{"key":"305_CR123","doi-asserted-by":"publisher","unstructured":"Tardy, M., Dold, M., Engel, R. R. & Leucht, S. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD009396.pub2 (2014).","DOI":"10.1002\/14651858.CD009396.pub2"},{"key":"305_CR124","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02933.x","volume":"67","author":"AK Eckstein","year":"2007","unstructured":"Eckstein, A. K. et al. Patients with severe Graves\u2019 ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin. Endocrinol. (Oxf.) 67, 607\u2013612 (2007).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"305_CR125","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1089\/thy.1999.9.1175","volume":"9","author":"DH Khoo","year":"1999","unstructured":"Khoo, D. H. et al. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves\u2019 disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 9, 1175\u20131180 (1999).","journal-title":"Thyroid"},{"key":"305_CR126","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1210\/jc.2018-02705","volume":"104","author":"GJ Kahaly","year":"2019","unstructured":"Kahaly, G. J., Wuster, C., Olivo, P. D. & Diana, T. High\u00a0titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with Graves disease. J. Clin. Endocrinol. Metab. 104, 2561\u20132568 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR127","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.ophtha.2011.03.030","volume":"118","author":"KA Ponto","year":"2011","unstructured":"Ponto, K. A. et al. Clinical relevance of thyroid-stimulating immunoglobulins in Graves\u2019 ophthalmopathy. Ophthalmology 118, 2279\u20132285 (2011).","journal-title":"Ophthalmology"},{"key":"305_CR128","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jcem.87.4.8411","volume":"87","author":"R Metcalfe","year":"2002","unstructured":"Metcalfe, R. et al. Demonstration of immunoglobulin G, A, and E autoantibodies to the human thyrotropin receptor using flow cytometry. J. Clin. Endocrinol. Metab. 87, 1754\u20131761 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR129","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1210\/jc.2012-1771","volume":"98","author":"WB Minich","year":"2013","unstructured":"Minich, W. B. et al. Autoantibodies to the IGF1 receptor in Graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 98, 752\u2013760 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40618-018-0943-8","volume":"42","author":"M Marino","year":"2019","unstructured":"Marino, M. et al. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves\u2019 disease and Graves\u2019 orbitopathy. J. Endocrinol. Invest. 42, 471\u2013480 (2019).","journal-title":"J. Endocrinol. Invest."},{"key":"305_CR131","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1210\/jc.2016-1882","volume":"101","author":"S Fang","year":"2016","unstructured":"Fang, S. et al. IL-17A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO. J. Clin. Endocrinol. Metab. 101, 2955\u20132965 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR132","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1210\/jc.2017-01349","volume":"102","author":"S Fang","year":"2017","unstructured":"Fang, S. et al. Regulation of orbital fibrosis and adipogenesis by pathogenic Th17 cells in graves orbitopathy. J. Clin. Endocrinol. Metab. 102, 4273\u20134283 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"305_CR133","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1055\/s-0035-1555956","volume":"47","author":"JP Banga","year":"2015","unstructured":"Banga, J. P., Moshkelgosha, S., Berchner-Pfannschmidt,\u00a0U. & Eckstein, A. Modeling Graves\u2019 orbitopathy in experimental Graves\u2019 disease. Horm. Metab. Res. 47, 797\u2013803 (2015).","journal-title":"Horm. Metab. Res."},{"key":"305_CR134","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/er.2013-1055","volume":"35","author":"SM McLachlan","year":"2014","unstructured":"McLachlan, S. M. & Rapoport, B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr. Rev. 35, 59\u2013105 (2014).","journal-title":"Endocr. Rev."},{"key":"305_CR135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/eje.0.1420001","volume":"142","author":"M Ludgate","year":"2000","unstructured":"Ludgate, M. Animal models of Graves\u2019 disease. Eur. J. Endocrinol. 142, 1\u20138 (2000).","journal-title":"Eur. J. Endocrinol."},{"key":"305_CR136","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.4049\/jimmunol.162.8.4966","volume":"162","author":"MC Many","year":"1999","unstructured":"Many, M. C. et al. Development of an animal model of autoimmune thyroid eye disease. J. Immunol. 162, 4966\u20134974 (1999).","journal-title":"J. Immunol."},{"key":"305_CR137","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1210\/en.2004-1015","volume":"146","author":"G Baker","year":"2005","unstructured":"Baker, G., Mazziotti, G., von Ruhland, C. & Ludgate, M. Reevaluating thyrotropin receptor-induced mouse models of graves\u2019 disease and ophthalmopathy. Endocrinology 146, 835\u2013844 (2005).","journal-title":"Endocrinology"},{"key":"305_CR138","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1530\/JOE-11-0162","volume":"210","author":"SX Zhao","year":"2011","unstructured":"Zhao, S. X. et al. Orbital fibrosis in a mouse model of\u00a0Graves\u2019 disease induced by genetic immunization of thyrotropin receptor cDNA. J. Endocrinol. 210, 369\u2013377 (2011).","journal-title":"J. Endocrinol."},{"key":"305_CR139","doi-asserted-by":"crossref","DOI":"10.1186\/s40168-018-0478-4","volume":"6","author":"G Masetti","year":"2018","unstructured":"Masetti, G. et al. Gut microbiota in experimental murine model of Graves\u2019 orbitopathy established in different environments may modulate clinical presentation of disease. Microbiome 6, 97 (2018).","journal-title":"Microbiome"},{"key":"305_CR140","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1097\/IOP.0000000000001148","volume":"34","author":"A Eckstein","year":"2018","unstructured":"Eckstein, A., Esser, J., Oeverhaus, M., Saeed, P. & Jellema, H. M. Surgical treatment of diplopia in Graves orbitopathy patients. Ophthalmic Plast. Reconstr. Surg. 34, S75\u2013S84 (2018).","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"305_CR141","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/09273972.2017.1318151","volume":"25","author":"L Barker","year":"2017","unstructured":"Barker, L., Mackenzie, K., Adams, G. G. & Hancox, J. Long-term surgical outcomes for vertical deviations in\u00a0thyroid eye disease. Strabismus 25, 67\u201372 (2017).","journal-title":"Strabismus"},{"key":"305_CR142","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bjo.83.1.81","volume":"83","author":"MP Mourits","year":"1999","unstructured":"Mourits, M. P. & Sasim, I. V. A single technique to correct various degrees of upper lid retraction in patients with Graves\u2019 orbitopathy. Br. J. Ophthalmol. 83, 81\u201384 (1999).","journal-title":"Br. J. Ophthalmol."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41574-019-0305-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41574-019-0305-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41574-019-0305-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T05:54:38Z","timestamp":1722232478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-019-0305-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,30]]},"references-count":142,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1038\/s41574-019-0305-4","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,30]]},"assertion":[{"value":"26 November 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Johannes Gutenberg University (JGU) Medical Center and the JGU Thyroid Laboratory received research grants from Novartis, Germany, and River Vision, USA, when performing the MINGO and teprotumumab trials.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}